Our Core Technology

Direct Antigen Presentation via Yeast for Treating and Preventing Disease (DAPYTAP)

At Ablatotech, we are at the forefront of a healthcare revolution, unlocking the body’s inherent capacity to heal itself and amplifying its natural resilience. Our groundbreaking platform, Direct Antigen Presentation via Yeast for the Treatment and Prevention of Disease (DAPYTAP), is redefining what is possible in modern medicine. With DAPYTAP, we are creating a new era of biotherapeutics—safe, highly effective drugs that are remarkably affordable. This innovation enables us to bring life-saving treatments to those in even the most underserved regions, ensuring that cutting-edge healthcare becomes a reality for all, not just a privilege for a few.

Ablatotech's vision goes beyond incremental improvements; we aim to disrupt and transform the healthcare industry by making healing accessible, equitable, and revolutionary. By bridging advanced science with practical solutions, we are delivering therapies that set new standards in efficacy and safety, while breaking cost barriers that have long limited global reach. Join us in reshaping the future of medicine—this is innovation with impact, innovation for humanity. Ablatotech is where science meets a profound commitment to improving lives on a global scale.

DAPYTAP is a better alternative to monoclonal antibody therapy

If it can be treated with monoclonal antibodies, it can be treated better with DAPYTAP. Some of the conditions that DAPYTAP might do much better than monoclonal antibodies include: (1) Kidney transplant rejection (2) Prevention of blood clots in angioplasty (3) Non-Hodgkin lymphoma (4) Prevention of respiratory syncytial virus infection (5) Crohn’s disease (6) Breast cancer (7) Chronic myeloid leukemia (8) Rheumatoid arthritis (9) Asthma (10) Colorectal cancer (11) Multiple sclerosis (12) Macular degeneration (13) Paroxysmal nocturnal hemoglobinuria (14) Psoriasis (15) Muckle-Wells syndrome (16) Rheumatoid and psoriatic arthritis (17) Ankylosing spondylitis (18) Chronic lymphocytic leukemia (19) Bone loss (20) Systemic lupus erythematosus (21) Metastatic melanoma (22) Hodgkin lymphoma (23) Systemic anaplastic large cell lymphoma (24) Castleman disease (25) Gastric cancer (26) Ulcerative colitis (27) Acute lymphoblastic leukemia (28) Non-small cell lung cancer (29) Neuroblastoma (30) Severe eosinophilic asthma (31) High cholesterol (32) Multiple myeloma (33) Soft tissue sarcoma (34) Prevention of Clostridium difficile infection recurrence (35) Bladder cancer (36) Prevention of inhalational anthrax (37) Atopic dermatitis (38) Merkel cell carcinoma (39) Multiple sclerosis (40) Hemophilia A (41) X-linked hypophosphatemia (42) Hereditary angioedema attacks (43) Mycosis fungoides (44) Sézary syndrome (45) Migraine prevention (46) Cutaneous squamous cell carcinoma (47) Primary hemophagocytic lymphohistiocytosis (48) HIV infection (49) Hairy cell leukemia (50) Acquired thrombotic thrombocytopenic purpura (51) Osteoporosis (52) Diffuse large B-cell lymphoma (53) Sickle cell disease